Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Index
-
Market Cap
11.98B
Enterprise Value
11.81B
Income
-11.80M
Sales
805.61M
Book/sh
36.90
Cash/sh
13.59
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
2000
IPO
Apr 29, 1986
P/E
-
Forward P/E
70.81
PEG
2.70
P/S
14.87
P/B
5.11
P/C
13.88
P/FCF
113.78
EV/EBITDA
72.92
EV/Sales
14.65
Quick Ratio
8.43
Current Ratio
9.88
Debt/Eq
0.33
LT Debt/Eq
0.32
Option/Short
Yes / Yes
EPS (ttm)
-0.21
EPS next Y
2.66
EPS next Q
0.52
EPS this Y
21.25%
EPS next Y
28.50%
EPS next 5Y
26.25%
EPS past 3/5Y
-35.60% -4.91%
Sales past 3/5Y
-2.70% 15.05%
EPS Y/Y TTM
-811.00%
Sales Y/Y TTM
13.80%
EPS Q/Q
-357.58%
Sales Q/Q
10.86%
Insider Own
5.56%
Insider Trans
-0.94%
Inst Own
111.61%
Inst Trans
5.17%
ROA
-0.40%
ROE
-0.57%
ROIC
-0.43%
Gross Margin
50.08%
Oper. Margin
8.58%
Profit Margin
-1.47%
SMA20
6.07%
SMA50
5.91%
SMA200
30.38%
Trades
Shs Outstand
63.49M
Shs Float
59.96M
52W High
198.87 -5.14%
52W Low
100.99 86.79%
Volatility
5.05% 5.51%
ATR (14)
8.73
RSI (14)
58.77
Beta
1.11
Rel Volume
0.00
Avg Volume
1.12M
Volume
0
Perf Week
5.56%
Perf Month
-1.87%
Perf Quarter
33.78%
Perf Half Y
59.45%
Perf YTD
15.12%
Perf Year
27.05%
Perf 3Y
57.75%
Perf 5Y
-35.06%
Perf 10Y
560.04%
Prev Close
188.64
Price
188.64
Change %
0.00%
Consensus
Buy
Avg. Price Target
$204.50
Implied Upside
+8.4%
Analysts15incl. previous ratings
Rating Distribution13 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 09, 2026Resumed
UBS logoUUBS
Buy$225+19.3%
Jul 07, 2026Upgrade
TThe Benchmark Company
Hold → Buy$185-1.9%
Jun 02, 2026Resumed
WWolfe Research
Outperform$145-23.1%
May 15, 2026Resumed
RY logoRRBC Capital Mkts
Outperform$160-15.2%
Apr 17, 2026Initiated
RRothschild & Co Redburn
Buy$160-15.2%
Oct 01, 2025Initiated
HSBC logoHHSBC Securities
Buy$150-20.5%
Sep 22, 2025Upgrade
EVR logoEEvercore ISI
In-line → Outperform$155-17.8%
Jul 22, 2025Resumed
SStephens
Overweight$160-15.2%
Jun 24, 2025Initiated
BCS logoBBarclays
Overweight$150-20.5%
Apr 29, 2025Upgrade
WWolfe Research
Peer Perform → Outperform$160-15.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Loeillot OlivierChief Executive OfficerOct 05 '26Option Exercise154.964,202651,14249,990Oct 06 04:18 PM
Loeillot OlivierChief Executive OfficerOct 05 '26Sale187.295,5351,036,65445,788Oct 06 04:18 PM
Loeillot OlivierOfficerOct 05 '26Proposed Sale190.004,202798,380Oct 05 04:10 PM
Loeillot OlivierOfficerOct 05 '26Proposed Sale178.751,333238,274Oct 05 01:14 PM
Loeillot OlivierChief Executive OfficerSep 24 '26Option Exercise155.1112,9462,008,02056,773Sep 25 04:09 PM
Loeillot OlivierChief Executive OfficerSep 24 '26Sale190.0012,9462,459,74048,369Sep 25 04:09 PM
Loeillot OlivierOfficerSep 24 '26Proposed Sale190.0012,9462,459,740Sep 24 05:04 PM
Loeillot OlivierChief Executive OfficerSep 21 '26Option Exercise141.795,426769,35353,795Sep 22 04:07 PM
Loeillot OlivierChief Executive OfficerSep 21 '26Sale180.005,426976,68048,369Sep 22 04:07 PM
Loeillot OlivierOfficerSep 21 '26Proposed Sale180.005,426976,680Sep 21 03:03 PM
Loeillot OlivierChief Executive OfficerSep 04 '26Sale165.903,035503,50648,369Sep 08 04:13 PM
Loeillot OlivierOfficerSep 04 '26Proposed Sale165.903,035503,506Sep 04 10:01 AM
Loeillot OlivierChief Executive OfficerAug 20 '26Option Exercise141.795,426769,35359,672Aug 21 04:06 PM
Loeillot OlivierChief Executive OfficerAug 20 '26Sale180.005,426976,68054,246Aug 21 04:06 PM
Loeillot OlivierOfficerAug 20 '26Proposed Sale180.005,426976,680Aug 20 11:53 AM
Garland Jason KCFOJul 16 '26Sale150.0053079,50018,829Jul 17 04:40 PM
Garland Jason KOfficerJul 16 '26Proposed Sale150.0053079,500Jul 16 01:45 PM
Garland Jason KCFOJun 25 '26Sale145.00733106,28519,359Jun 26 04:05 PM
Garland Jason KOfficerJun 25 '26Proposed Sale145.00733106,285Jun 25 01:55 PM
MUIR GLENN PDirectorMay 07 '26Option Exercise38.762,43494,34239,056May 08 02:48 PM
Loeillot OlivierChief Executive OfficerApr 21 '26Sale140.003,832536,48054,246Apr 22 01:26 PM
Loeillot OlivierOfficerApr 21 '26Proposed Sale140.003,832536,480Apr 21 12:44 PM
DAWES KAREN ADirectorDec 17 '25Sale161.0027544,27591,821Dec 18 04:30 PM
MUIR GLENN PDirectorDec 16 '25Option Exercise26.123,36687,92036,622Dec 17 04:30 PM
DAWES KAREN ADirectorDec 17 '25Proposed Sale161.0027544,275Dec 17 04:28 PM
Loeillot OlivierChief Executive OfficerNov 25 '25Sale170.007,0411,196,97035,898Nov 26 04:30 PM
Loeillot OlivierOfficerNov 25 '25Proposed Sale170.007,0411,196,970Nov 25 12:06 PM
Bylund JamesChief Operating OfficerNov 18 '25Sale151.212,191331,30121,520Nov 19 04:30 PM
Bylund JamesOfficerNov 18 '25Proposed Sale151.212,191331,304Nov 18 04:10 PM
Hunt AnthonyDirectorNov 13 '25Option Exercise33.872,95299,98483,695Nov 14 04:30 PM
Hunt AnthonyDirectorNov 13 '25Sale154.6120,0003,092,27880,743Nov 14 04:30 PM
Hunt AnthonyDirectorNov 12 '25Option Exercise33.8725,000846,750125,743Nov 13 04:30 PM
Hunt AnthonyDirectorNov 12 '25Sale156.8825,0003,921,940100,743Nov 13 04:30 PM
Hunt AnthonyDirectorNov 13 '25Proposed Sale154.6220,0003,092,327Nov 13 04:11 PM
Hunt AnthonyDirectorNov 12 '25Proposed Sale156.8825,0003,921,981Nov 12 04:37 PM
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
PresidentMr. Olivier Loeillot
CFO & Chief Compliance OfficerMr. Jason K. Garland
Chief Operating OfficerMr. James R. Bylund
AdvisorMr. Anthony J. Hunt
Senior Vice President of Research & DevelopmentMr. Ralf Kuriyel